Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vericel

39.42
-1.4500-3.55%
Post-market: 39.420.00000.00%16:36 EDT
Volume:502.89K
Turnover:19.99M
Market Cap:1.98B
PE:197.10
High:41.79
Open:41.55
Low:39.32
Close:40.87
Loading ...

Company Profile

Company Name:
Vericel
Exchange:
NASDAQ
Establishment Date:
1989
Employees:
357
Office Location:
64 Sidney Street,Cambridge,Massachusetts,United States
Zip Code:
02139
Fax:
617 588 5554
Introduction:
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Directors

Name
Position
Dominick C. Colangelo
Director, President and Chief Executive Officer
Robert L. Zerbe
Independent Director, Chairman of the Board
Alan L. Rubino
Independent Director
Heidi Hagen
Independent Director
Kevin McLaughlin
Independent Director
Lisa Wright
Independent Director
Paul Wotton
Independent Director
Steven Gilman
Independent Director

Shareholders

Name
Position
Dominick C. Colangelo
Director, President and Chief Executive Officer
Michael Halpin
Chief Operating Officer
Joe Mara
Chief Financial Officer
Sean C. Flynn
Senior Vice President, General Counsel and Secretary
Jonathan Hopper
Chief Medical Officer